Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Blarcamesine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anavex Life's Acceptance of Blarcamesine Phase IIb/III Data Manuscript
    Anavex Life's Acceptance of Blarcamesine Phase IIb/III Data Manuscript

    25 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/25/2986572/29248/en/Anavex-Life-Sciences-Announces-Acceptance-of-Peer-Reviewed-Manuscript-of-Oral-Blarcamesine-Phase-IIb-III-Data-in-a-Reference-Alzheimer-s-Disease-Journal.html

    GLOBENEWSWIRE
    25 Nov 2024
    Share Share
    NANOBIOTIX to Attend Investor Conferences in November
    NANOBIOTIX to Attend Investor Conferences in November

    31 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/31/2972317/0/en/NANOBIOTIX-to-Participate-in-Multiple-Investor-Conferences-in-November.html

    GLOBENEWSWIRE
    31 Oct 2024
    Share Share
    Anavex Presents ANAVEX®2-73 Biomarker Data In Fragile X Syndrome
    Anavex Presents ANAVEX®2-73 Biomarker Data In Fragile X Syndrome

    30 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/30/2920900/29248/en/Anavex-Life-Sciences-Announces-Translational-Biomarker-Data-for-ANAVEX-2-73-blarcamesine-in-Fragile-X-Syndrome-Major-Cause-of-Autism-at-the-19th-NFXF-International-Fragile-X-Confer.html

    GLOBENEWSWIRE
    30 Jul 2024
    Share Share
    Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine
    Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine

    08 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/08/2805328/29248/en/Anavex-Life-Sciences-Announces-Grant-of-U-S-Patent-Covering-Blarcamesine-ANAVEX-2-73-for-Treatment-of-Neurodevelopmental-Disorders.html

    GLOBENEWSWIRE
    08 Jan 2024
    Share Share
    Anavex’s experimental drug fails Rett syndrome study, stock falls
    Anavex’s experimental drug fails Rett syndrome study, stock falls

    03 Jan 2024

    // ENDPTS

    https://endpts.com/anavexs-experimental-drug-fails-rett-syndrome-study-stock-falls/

    ENDPTS
    03 Jan 2024
    Share Share
    Anavex Received Agreement from CHMP for Submission of a MAA of Oral Blarcamesine
    Anavex Received Agreement from CHMP for Submission of a MAA of Oral Blarcamesine

    19 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/19/2798446/29248/en/Anavex-Received-Agreement-from-the-Committee-for-Medicinal-Products-for-Human-Use-CHMP-for-the-Submission-of-a-Marketing-Authorisation-Application-of-Oral-Blarcamesine-for-Alzheime.html

    GLOBENEWSWIRE
    19 Dec 2023
    Share Share